Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - primaquine phosphate -

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - paracetamol, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; mannitol; sodium hydroxide; dibasic sodium phosphate dihydrate; povidone - paracetamol bnm 1000mg/100ml, solution for infusion is indicated for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - acarbose 100mg;   - tablet - 100 mg - active: acarbose 100mg   excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose pregelatinised maize starch - indicated for the additional treatment of insulin dependent and non-insulin dependent diabetes mellitus in association with diet.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - acarbose 50mg;   - tablet - 50 mg - active: acarbose 50mg   excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose pregelatinised maize starch - indicated for the additional treatment of insulin dependent and non-insulin dependent diabetes mellitus in association with diet.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine; tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine - film coated tablet - 10 mg - active: tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine excipient: calcium sulfate carnauba wax red spectraspray acsl0673 erythrosine gelatin hypromellose magnesium stearate maize starch propylene glycol shellac sucrose active: tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine excipient: calcium sulfate carnauba wax erythrosine gelatin magnesium stearate maize starch opadry red 06h250000 sucrose - parnate is indicated for the treatment of symptoms of depressive illness especially where treatment with other types of anti-depressants has failed. it is not recommended for use in mild depressive states resulting from temporary situational difficulties.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - trifluoperazine hydrochloride 1.18mg equivalent to 1 mg trifluoperazine;   - film coated tablet - 1 mg - active: trifluoperazine hydrochloride 1.18mg equivalent to 1 mg trifluoperazine   excipient: calcium sulfate dihydrate gelatin maize starch opadry blue oy-4492 purified talc purified water as solvent stearic acid sucrose - chronic therapy in high doses for management of manifestations of psychotic disorders, such as acute and chronic catatonic hebephrenic and paranoid schizophrenia, psychosis due to organic brain damage, toxic psychosis, manic depressive psychosis, senile psychosis and mental deficiency. short-term therapy treatment of acute alcoholism for the relief of delusons, hallucinations and confused state, and for the control of accompanying tremulousness and aggressive behaviour. in low doses to control excessive anxiety, tension and agitation as seen in neuroses or associated with somatic conditions. stelazine is not recommended as first line therapy in patients with non-psychotic anxiety disorders, nor should therapy be carried out for more than 12 weeks. for nausea and vomiting of various causes.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - trifluoperazine hydrochloride 2.36mg equivalent to 2 mg trifluoperazine;   - film coated tablet - 2 mg - active: trifluoperazine hydrochloride 2.36mg equivalent to 2 mg trifluoperazine   excipient: calcium sulfate dihydrate gelatin maize starch opadry blue oy-4492 purified talc purified water as solvent stearic acid sucrose - chronic therapy in high doses for management of manifestations of psychotic disorders, such as acute and chronic catatonic hebephrenic and paranoid schizophrenia, psychosis due to organic brain damage, toxic psychosis, manic depressive psychosis, senile psychosis and mental deficiency. short-term therapy treatment of acute alcoholism for the relief of delusons, hallucinations and confused state, and for the control of accompanying tremulousness and aggressive behaviour. in low doses to control excessive anxiety, tension and agitation as seen in neuroses or associated with somatic conditions. stelazine is not recommended as first line therapy in patients with non-psychotic anxiety disorders, nor should therapy be carried out for more than 12 weeks. for nausea and vomiting of various causes.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - trifluoperazine hydrochloride 5.9mg equivalent to 5 mg trifluoperazine;   - film coated tablet - 5 mg - active: trifluoperazine hydrochloride 5.9mg equivalent to 5 mg trifluoperazine   excipient: calcium sulfate dihydrate gelatin maize starch opadry blue oy-4492 purified talc purified water as solvent stearic acid sucrose - chronic therapy in high doses for management of manifestations of psychotic disorders, such as acute and chronic catatonic hebephrenic and paranoid schizophrenia, psychosis due to organic brain damage, toxic psychosis, manic depressive psychosis, senile psychosis and mental deficiency. short-term therapy treatment of acute alcoholism for the relief of delusons, hallucinations and confused state, and for the control of accompanying tremulousness and aggressive behaviour. in low doses to control excessive anxiety, tension and agitation as seen in neuroses or associated with somatic conditions. stelazine is not recommended as first line therapy in patients with non-psychotic anxiety disorders, nor should therapy be carried out for more than 12 weeks. for nausea and vomiting of various causes.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - baclofen, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - sintetica baclofen intrathecal is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - baclofen, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - sintetica baclofen intrathecal is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.